Menlo Park-based Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay ...

Summit Therapeutics (NASDAQ: SMMT) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of ...

MIAMI, March 17, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial ...

MIAMI - Summit Therapeutics Inc. (NASDAQ: SMMT), a biopharmaceutical company specializing in oncology with a market capitalization of $14.2 billion, disclosed the grant of inducement stock options to ...

MIAMI - Summit Therapeutics Inc. (NASDAQ: SMMT), a biopharmaceutical company specializing in oncology with a market capitalization of $14.2 billion, disclosed the grant of inducement stock options ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 122,650 shares of ...

One analyst feels the shares have upside potential approaching 60%. He initiated coverage of Summit with a confident buy recommendation. The person behind the news was Evercore ISI pundit Cory ...

A very bullish analyst move was the news generally responsible for Summit Therapeutics' (NASDAQ: SMMT) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before ...